When Tumor Infiltrating Lymphocytes (TILs) are treated with checkpoint inhibitors and co-stimulated with the TNFR binding protein 4-1BB, these T cells raise the SRC, exhibit both mitogenesis and mitochondrial fusion, and provide greater anti-tumor activity than TILs treated with checkpoint inhibitors alone [60]. The gene discussed is SRC; the disease is neoplasm.